Technical Analysis for CSSPF - Circassia Pharmaceutical Plc

Grade Last Price % Change Price Change
grade B 0.28 8.61% 0.0222
CSSPF closed up 8.61 percent on Thursday, August 1, 2019, on 2.5 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A N/A Up
See historical CSSPF trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Narrow Range Bar Range Contraction 8.61%
Wide Bands Range Expansion 8.61%
Gapped Up Strength 8.61%
Hot IPO Pullback Bullish Swing Setup 12.00%
Narrow Range Bar Range Contraction 12.00%
Wide Bands Range Expansion 12.00%

Older signals for CSSPF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally. The company's asthma products comprise Fliveo that targets substitution of Flixotide, which has approved in the United Kingdom, as well as developing Seriveo that targets direct substitution of Seretide. It is also developing various novel specialty treatments for COPD, including Spiriva substitute, Novel LABA/LAMA formulation, and novel COPD therapy formulation. In addition, the company' development pipeline includes a range of treatments for allergies, such as cat allergy, grass allergy, house dust mite allergy, and ragweed allergy. It has a collaboration agreement with AstraZeneca to promote Tudorza for COPD treatment, and has the US commercial rights to late-stage COPD product Duaklir. Circassia Pharmaceuticals plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.
Medicine RTT Medical Specialties Clinical Medicine Biopharmaceutical Alcohols Asthma Chronic Obstructive Pulmonary Disease Allergies Respiratory Diseases Astrazeneca Chronic Lower Respiratory Diseases Combination Drugs Copd Treatment Of Asthma And Chronic Obstructive Pulmonary Disease
Is CSSPF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 1.3
52 Week Low 0.199
Average Volume 40,044
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.3036
10-Day Moving Average 0.2503
Average True Range 0.061
ADX 46.67
+DI 28.944
-DI 71.0794
Chandelier Exit (Long, 3 ATRs ) 1.107
Chandelier Exit (Short, 3 ATRs ) 0.382
Upper Bollinger Band 0.5994
Lower Bollinger Band 0.0078
Percent B (%b) 0.46
BandWidth 194.86166
MACD Line -0.203
MACD Signal Line -0.1979
MACD Histogram -0.0051
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.2800
Resistance 3 (R3) 0.2800 0.2800 0.2800
Resistance 2 (R2) 0.2800 0.2800 0.2800 0.2800
Resistance 1 (R1) 0.2800 0.2800 0.2800 0.2800 0.2800
Pivot Point 0.2800 0.2800 0.2800 0.2800 0.2800
Support 1 (S1) 0.2800 0.2800 0.2800 0.2800 0.2800
Support 2 (S2) 0.2800 0.2800 0.2800 0.2800
Support 3 (S3) 0.2800 0.2800 0.2800
Support 4 (S4) 0.2800